Operose Advisors LLC Acquires New Stake in ImmunityBio, Inc. $IBRX

Posted by Geri Gentry on Sep 6th, 2026

Operose Advisors LLC acquired a new stake in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 62,057 shares of the company’s stock, valued at approximately $543,000.

Several other institutional investors and hedge funds have also made changes to their positions in IBRX. BlackRock Inc. grew its holdings in shares of ImmunityBio by 29.4% in the second quarter. BlackRock Inc. now owns 34,083,262 shares of the company’s stock worth $298,399,000 after purchasing an additional 7,736,819 shares during the last quarter. Vanguard Group Inc. boosted its position in ImmunityBio by 18.5% in the 4th quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company’s stock valued at $64,899,000 after buying an additional 5,122,052 shares during the period. State Street Corp boosted its position in ImmunityBio by 45.4% in the 4th quarter. State Street Corp now owns 16,455,703 shares of the company’s stock valued at $32,582,000 after buying an additional 5,139,890 shares during the period. Geode Capital Management LLC grew its stake in ImmunityBio by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company’s stock worth $15,684,000 after acquiring an additional 1,030,113 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in ImmunityBio by 439.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company’s stock worth $12,182,000 after acquiring an additional 5,012,001 shares in the last quarter. 8.58% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other ImmunityBio news, Director Barry J. Simon sold 25,000 shares of ImmunityBio stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $7.88, for a total value of $197,000.00. Following the transaction, the director directly owned 2,802,788 shares of the company’s stock, valued at approximately $22,085,969.44. The trade was a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 131,210 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $9.50, for a total value of $1,246,495.00. Following the transaction, the director directly owned 125,386 shares in the company, valued at approximately $1,191,167. The trade was a 51.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 412,410 shares of company stock worth $3,753,442 in the last 90 days. 66.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on IBRX. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of ImmunityBio in a research note on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of ImmunityBio in a research note on Friday, July 10th. Finally, BTIG Research restated a “buy” rating and set a $12.00 price objective on shares of ImmunityBio in a report on Thursday, May 21st. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.20.

Get Our Latest Analysis on IBRX

ImmunityBio Trading Down 1.3%

IBRX opened at $8.08 on Friday. The firm has a market cap of $8.56 billion, a price-to-earnings ratio of -8.33 and a beta of 0.04. ImmunityBio, Inc. has a 12 month low of $1.95 and a 12 month high of $12.43. The stock has a fifty day moving average price of $7.90 and a 200-day moving average price of $7.88.

ImmunityBio (NASDAQ:IBRX – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The company had revenue of $51.24 million during the quarter, compared to the consensus estimate of $49.70 million. On average, equities research analysts forecast that ImmunityBio, Inc. will post -0.44 EPS for the current year.

About ImmunityBio

(Free Report)

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.